Back to News
M&A

Drinks With The Deal: Cleary Gottlieb's Jim Langston

|
Published: August 5th, 2021
Cleary Gottlieb's Jim Langston on the latest Drinks With The Deal podcast discusses how companies are responding to more vigorous antitrust enforcement.

“Antitrust is probably the highest-stakes issue in M&A today,” James Langston said on this week’s Drinks With The Deal podcast. “Across the globe, many regulators are taking a harder look at translations. Wherever you turn, it seems that big is now bad.”

Merging parties need to respond, said Langston, a partner at Cleary Gottlieb Steen & Hamilton LLP in New York. “Buyers and sellers need to have their eyes wide open. They need to have a strategy for getting the deal done, and they need to think about the regulatory process from a communications planning perspective, how they’re going to sell the deal not just to regulators but to government officials and other stakeholders. They need to be willing to advocate for the deal they believe in early and often and in a manner that reflects this new environment.”

Companies are responding to an environment in which “regulators have also been asking questions about deals they haven’t asked in the past,” Langston said, about issues that go beyond the consumer welfare standard that has been the focus of antitrust analysis for at least 40 years. “We’ll see if that’s just a shift in tone or a harbinger of something bigger.”

Here’s the podcast with James Langston:

More podcasts from The Deal are available on iTunes, Spotify and on TheDeal.com.

More From M&A

M&A

Deal Diary: Cleary, Paul Weiss on CPP Sale to GE Aerospace

By David Marcus
|
Published: September 16th, 2026
Warburg Pincus and Berkshire Partners portfolio company CPP taps Cleary on an $11.75 billion agreement to sell to GE Aerospace, which uses Paul Weiss. The Deal in July reported CPP was exploring strategic options.
M&A

Deal Diary: Centerview, Legal Trio Work Precision Medicine Sale

By David Marcus
|
Published: August 25th, 2026
Blackstone holding Precision Medicine taps Centerview and Simpson Thacher on a $2.25 billion agreement to sell to McKesson, which uses Davis Polk. The Deal reported in January that Blackstone had tapped Centerview to run an auction.